---
layout: post
title: 2010 New Drug Approvals - Pt. XVII- Eribulin Mesylate (Halaven)
date: '2010-11-19T07:17:00.016Z'
author: Bissan Al-Lazikani
tags:
- Natural Product Drugs
- 2010 New Drugs
modified_time: '2010-12-24T09:02:48.329Z'
thumbnail: http://3.bp.blogspot.com/_C1R117pBhNQ/TOTPtiNesJI/AAAAAAAAABg/2PLjF6LYuUE/s72-c/Halaven.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6715270633475991728
blogger_orig_url: http://chembl.blogspot.com/2010/11/2010-new-drug-approvals-pt-xvii.html
---

<a href="http://3.bp.blogspot.com/_C1R117pBhNQ/TOTPtiNesJI/AAAAAAAAABg/2PLjF6LYuUE/s1600/Halaven.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5540781822756958354" src="http://3.bp.blogspot.com/_C1R117pBhNQ/TOTPtiNesJI/AAAAAAAAABg/2PLjF6LYuUE/s200/Halaven.png" style="cursor: hand; cursor: pointer; display: block; height: 189px; margin: 0px auto 10px; text-align: center; width: 130px;" /></a>  <br />
<br />
<br />
<center><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/7,0,0,0,1,0,1,0,0" width="95%&quot;" /></center><center><br />
<center>ATC code (partial): L01C</center> <br />
</center>  On November 15th, 2010, the FDA approved Eribulin Mesylate (ResearchCode:E-7389) under the trade name Halaven (TradeMark:<a href="http://www.trademarkia.com/trademarks-search.aspx?tn=halaven">Halaven</a>).  It is indicated for for the treatment of patients with late stage, metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Phase III trials showed that patients survived a median of 2.5 months longer than patients treated with other current alternatives.   Eribuln is a synthethic analogue of <a href="http://en.wikipedia.org/wiki/Halichondrin">halichondrin B</a>, a cytotoxic polyether macrolide marine natural product.<br />
<div><br />
</div><div>The mechanism of action of Eribulin is anti-mitotic and is mediated <i>via</i> tubulin binding, where it leads to G2/M block in the the <a href="http://en.wikipedia.org/wiki/Cell_cycle">cell-cycle</a>;&nbsp;after prolonged stalling in this state, cells enter <a href="http://en.wikipedia.org/wiki/Apoptosis">apoptosis</a> and are then cleared.<br />
<br />
<div><div class="separator" style="clear: both; text-align: center;"><a href="http://3.bp.blogspot.com/_SlPG9DIz_AA/TOZKvrhvyJI/AAAAAAAAA7U/oX7PtmC_X-M/s1600/eri.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="241" src="http://3.bp.blogspot.com/_SlPG9DIz_AA/TOZKvrhvyJI/AAAAAAAAA7U/oX7PtmC_X-M/s320/eri.png" width="320" /></a></div><div style="text-align: center;"><br />
</div>Eribulin is a large (Mwt 729.9 for Eribulin and 826.0 for the mesylate salt) synthetic compound (an analogue of halichondrin B) an IUPAC name of the structure is 11,15:18,21:24,28­ Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3­ b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3­ methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt). The most striking part of the structure is the highly fused, rigid ring system, as you would expect, the <a href="http://pipeline.corante.com/archives/2010/11/18/halaven_holder_of_the_record.php">synthesis is complicated</a>. The structure contains many of the classical features of natural products - a high number and fraction of defined chiral centers, a high ratio of oxygens to nitrogens, and a high ring count.</div><div><br />
</div><div>The recommended dosing is 1.4mg/m2 as two intravenously delivered doses, separated by seven days, repeated after a further two weeks. An average adult human has a skin surface area of <i>ca.</i> 1.8 m2, so this would equate to a single dose of ~3 umol) &nbsp;The mean half-life of Eribulin is ~40 hr, with a mean volume of distribution of ~80 L/m2, and a mean clearance of ~1.8 L/hr/m2. Plasma protein binding is around 58%. Eribulin is metabolically stable and is largely unmetabolised, with the majority of the dosed drug being excreted as the dosed form in the feces.<br />
<span class="Apple-style-span" style="font-family: 'Times New Roman'; font-size: x-small;"><span class="Apple-style-span" style="font-size: 10px;"><span class="Apple-style-span" style="font-family: Times;"><span class="Apple-style-span" style="font-size: small;"><br />
</span></span></span></span></div><div>Eribulin binds at (or near) the vinca domain of tubulin, a region that is located at the interface of two tubulin heterodimers when arranged end to end and overlaps the exchangeable GTP site on β-tubulin (<a href="http://www.ncbi.nlm.nih.gov/pubmed/1874739">Bai et al</a>).  β-tubulin is small family of related human proteins (PFAM:<a href="http://pfam.sanger.ac.uk/family/PF03953">PF03953</a>, HOMSTRAD:<a href="http://tardis.nibio.go.jp/cgi-bin/homstrad/showpage.cgi?family=tubulin&amp;disp=str">tubulin</a>,&nbsp;and UniProt:<a href="http://www.uniprot.org/uniprot/P07437">P07437</a>&nbsp;for a specific member) that are key components of <a href="http://en.wikipedia.org/wiki/Microtubules">microtubules</a>. There are multiple isoforms of β-tubulin <i>e.g.</i> "tubulin-beta1" , ChEMBLDB ID: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/CHEMBL1915">CHEMBL1915</a>, canSAR:<a href="https://cansar.icr.ac.uk/index.php?redirect=treport&amp;redirect_value=Q9H4B7">link</a>; and "tubulin-beta5", ChEMBLDB_ID:<a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/CHEMBL5444">CHEMBL5444</a>, canSAR <a href="https://cansar.icr.ac.uk/index.php?redirect=treport&amp;redirect_value=P07437">link</a>. Multiple 3-D structures are available for alpha-/beta-tubulins including PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1tub/summary.html">1tub</a>.&nbsp;Tubulins are the target of several other classes of anticancer drugs, such as <a href="http://en.wikipedia.org/wiki/Taxol">Paclitaxel</a> (aka taxol) and <a href="http://en.wikipedia.org/wiki/Vinblastine">Vinblastine</a> (both similarly cytotoxic natural products)</div><div><br />
&nbsp;   <a href="http://2.bp.blogspot.com/_C1R117pBhNQ/TOUexWEB4kI/AAAAAAAAABw/29w2nyyetQU/s1600/tub.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5540868749634167362" src="http://2.bp.blogspot.com/_C1R117pBhNQ/TOUexWEB4kI/AAAAAAAAABw/29w2nyyetQU/s200/tub.png" style="cursor: hand; cursor: pointer; display: block; height: 182px; margin: 0px auto 10px; text-align: center; width: 200px;" /></a>    <br />
<pre></pre><pre>NAME="Eribulin Mesylate"
TRADEMARK_NAME="Halaven"
ATC_code= L01C
SMILES="CO[C@@H]([C@@H](C[C@H](O)CN)O1)[C@@H](CC(C[C@@H]2O[C@@]([C@H]3C4[C@@]([C@@H]5[C@@H](C6)O4)([H])O7)([H])[C@]7([H])CC2)=O)[C@@H]1C[C@@H](O[C@@H](CC[C@H]8C(C[C@H](CC[C@]6(O5)O3)O8)=C)C[C@H]9C)C9=C.CS(O)(=O)=O"
InChI="/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38?,39+,40+;/m1./s1/i1-12,2-12,3-12,4-12,5-12,6-12,7-12,8-12,9-12,10-12,11-12,12-12,13-12,14-12,15-12,16-12,17-12,18-12,19-12,20-12,21-12,22-12,23-12,24-12,25-12,26-12,27-12,28-12,29-12,30-12,31-12,32-12,33-12,34-12,35-12,36-12,37-12,38-12,39-12,40-12,41-14,42-16,43-16,44-16,45-16,46-16,47-16,48-16,49-16,50-16,51-16,52-16;1-12,2-16,3-16,4-16,5-32"
ChemDraw=eribulin.cdx
</pre><br />
Full prescribing information <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf">here</a>  The license holder for Halaven™ is  <a href="http://www.eisai.co.jp/index-e.html">Eisai Inc.</a>   </div></div>